Skip to main content
Medical information Clinical review pending

Genetic Testing

PPARG Gene Lipodystrophy Familial Partial Type 3 Genetic Test

This genetic test identifies mutations in the PPARG gene associated with Familial Partial Lipodystrophy Type 3, a metabolic disorder affecting fat distribution. Understanding your genetic risk helps in early diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
No specific fasting is required. A genetic counseling session is recommended before the test to discuss family history and the implications of testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the PPARG Gene Lipodystrophy Familial Partial Type 3 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of lipodystrophy.
  • ✓Patients presenting with symptoms suggestive of lipodystrophy (e.g., unusual fat distribution, insulin resistance).
  • ✓Individuals seeking genetic confirmation for suspected Familial Partial Lipodystrophy Type 3.
  • ✓Patients with metabolic syndrome or related conditions where lipodystrophy is suspected.
  • ✓Family members of individuals diagnosed with PPARG-related lipodystrophy.
02

In plain language

What this test helps you understand

This test helps identify specific mutations in the PPARG gene linked to Familial Partial Lipodystrophy Type 3. This information can aid in confirming a diagnosis, understanding the genetic basis of the condition, and guiding management strategies.
The PPARG Gene Lipodystrophy Familial Partial Type 3 NGS Genetic DNA Test is a specialized genetic analysis designed to detect mutations within the PPARG gene. These mutations are linked to Familial Partial Lipodystrophy Type 3, a condition characterized by abnormal fat distribution and associated metabolic complications. This test provides crucial information for individuals concerned about this specific genetic disorder.

This test focuses on identifying specific genetic variations in the PPARG gene that can contribute to the development of lipodystrophy. By analyzing your DNA, we aim to pinpoint the genetic cause, which can significantly influence diagnosis and treatment strategies.

Understanding your genetic predisposition to Familial Partial Lipodystrophy Type 3 is vital for proactive health management. Early detection allows for timely intervention and personalized care plans to mitigate potential health risks associated with the condition.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific fasting is required. A genetic counseling session is recommended before the test to discuss family history and the implications of testing.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) of the PPARG gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the PPARG gene. Other genes or factors may contribute to lipodystrophy or similar conditions. A negative result does not completely rule out a genetic cause for lipodystrophy. The test may not detect all possible mutations within the PPARG gene.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

It is a genetic disorder affecting how the body stores and uses fat, leading to abnormal fat distribution and potential metabolic problems like insulin resistance.
Identifying the specific gene mutation (like in PPARG) helps confirm the diagnosis, understand the cause, and guide appropriate management and counseling for the individual and family.
Individuals with symptoms of lipodystrophy, a family history of the condition, or related metabolic issues should discuss this test with their doctor.
The test analyzes a sample of your DNA (usually from a blood sample) to look for specific changes in the PPARG gene.
Results will indicate if specific mutations in the PPARG gene were found. A healthcare professional, often a geneticist, will help interpret the results in the context of your health history.
Yes, genetic counseling before and after the test is highly recommended to understand the test's implications, interpret results, and discuss family planning or screening.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp